These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38011021)

  • 1. Aripiprazole and Other Third-Generation Antipsychotics as a Risk Factor for Impulse Control Disorders: A Systematic Review and Meta-Analysis.
    Williams BD; Lee K; Ewah SO; Neelam K
    J Clin Psychopharmacol; 2024 Jan-Feb 01; 44(1):39-48. PubMed ID: 38011021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System.
    Fusaroli M; Raschi E; Giunchi V; Menchetti M; Rimondini Giorgini R; De Ponti F; Poluzzi E
    Int J Neuropsychopharmacol; 2022 Sep; 25(9):727-736. PubMed ID: 35639870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aripiprazole and impulse control disorders: higher risk with the intramuscular depot formulation?
    Lertxundi U; Hernandez R; Medrano J; Domingo-Echaburu S; Garcia M; Aguirre C
    Int Clin Psychopharmacol; 2018 Jan; 33(1):56-58. PubMed ID: 28777129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do cariprazine and brexpiprazole cause impulse control symptoms? A case/non-case study.
    Zazu L; Morera-Herreras T; Garcia M; Aguirre C; Lertxundi U
    Eur Neuropsychopharmacol; 2021 Sep; 50():107-111. PubMed ID: 34082277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis.
    Demyttenaere K; Detraux J; Racagni G; Vansteelandt K
    CNS Drugs; 2019 Jun; 33(6):549-566. PubMed ID: 31065941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia.
    Keks N; Hope J; Schwartz D; McLennan H; Copolov D; Meadows G
    CNS Drugs; 2020 May; 34(5):473-507. PubMed ID: 32246399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aripiprazole and impulse-control disorders in high-risk patients.
    Mohan T; Dolan S; Mohan R; Dawson J
    Asian J Psychiatr; 2017 Jun; 27():67-68. PubMed ID: 28558898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Partial dopamine agonist-induced pathological gambling and impulse-control deficit on low-dose aripiprazole.
    Peterson E; Forlano R
    Australas Psychiatry; 2017 Dec; 25(6):614-616. PubMed ID: 28696131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Data on the Adverse Metabolic Effects of Second-Generation Antipsychotics and Their Potential Determinants in Adult Patients: A Systematic Review of Population-Based Studies.
    Bernardo M; Rico-Villademoros F; García-Rizo C; Rojo R; Gómez-Huelgas R
    Adv Ther; 2021 May; 38(5):2491-2512. PubMed ID: 33826090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Third-generation antipsychotics in patients with schizophrenia and non-responsivity or intolerance to clozapine regimen: What is the evidence?
    Vasiliu O
    Front Psychiatry; 2022; 13():1069432. PubMed ID: 36523870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antipsychotics for cocaine or psychostimulant dependence: systematic review and meta-analysis of randomized, placebo-controlled trials.
    Kishi T; Matsuda Y; Iwata N; Correll CU
    J Clin Psychiatry; 2013 Dec; 74(12):e1169-80. PubMed ID: 24434105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants.
    Ostuzzi G; Bertolini F; Tedeschi F; Vita G; Brambilla P; Del Fabro L; Gastaldon C; Papola D; Purgato M; Nosari G; Del Giovane C; Correll CU; Barbui C
    World Psychiatry; 2022 Jun; 21(2):295-307. PubMed ID: 35524620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy?
    Mohr P; Masopust J; Kopeček M
    Front Psychiatry; 2021; 12():781946. PubMed ID: 35145438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aripiprazole for autism spectrum disorders (ASD).
    Hirsch LE; Pringsheim T
    Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD009043. PubMed ID: 27344135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.
    Declercq T; Petrovic M; Azermai M; Vander Stichele R; De Sutter AI; van Driel ML; Christiaens T
    Cochrane Database Syst Rev; 2013 Mar; (3):CD007726. PubMed ID: 23543555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical antipsychotics for disruptive behaviour disorders in children and youths.
    Loy JH; Merry SN; Hetrick SE; Stasiak K
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD008559. PubMed ID: 28791693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the underlying mechanisms of drug-induced impulse control disorders: a pharmacovigilance-pharmacodynamic study.
    Fusaroli M; Giunchi V; Battini V; Gringeri M; Rimondini R; Menchetti M; Radice S; Pozzi M; Nobile M; Clementi E; De Ponti F; Carnovale C; Raschi E; Poluzzi E
    Psychiatry Clin Neurosci; 2023 Mar; 77(3):160-167. PubMed ID: 36436204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials.
    Pringsheim T; Lam D; Ching H; Patten S
    Drug Saf; 2011 Aug; 34(8):651-68. PubMed ID: 21751826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.